表紙
市場調査レポート

バイオバンキング市場の予測 (2016-2026年):医療研究・治療のためのヒトの体液・組織・幹細胞利用の展望

Biobanking Market Forecasts 2016-2026: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells

発行 Visiongain Ltd 商品コード 229862
出版日 ページ情報 英文 249 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.81円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
バイオバンキング市場の予測 (2016-2026年):医療研究・治療のためのヒトの体液・組織・幹細胞利用の展望 Biobanking Market Forecasts 2016-2026: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells
出版日: 2016年04月26日 ページ情報: 英文 249 Pages
概要

2020年における世界のバイオバンキングの市場は275億ドルの規模に達すると予測されています。特に製薬企業による前臨床研修のための生体試料の需要の拡大が同市場の収益増を推進しています。

当レポートでは、世界のバイオバンキングの市場を調査し、バイオバンキングの定義と用途、用途・地域/主要国別の動向および市場規模の推移と予測、バイオバンキング関連技術 (システム・ソフトウェア・消耗品・サービス) の動向、主要企業のプロファイル、定性分析、専門家へのインタビュー、将来の展望などをまとめています。

第1章 レポート概要

第2章 イントロダクション:バイオバンキングとその用途

  • ヒト組織バンキング市場の定義
  • 幹細胞バンキング市場の定義
  • バイオバンキングとは?
  • バイオバンクの主な特性
  • バイオバンキングに含まれるプロセスとは?
  • バイオバンクの分類:細胞の種類、ボランティア団体・組織分類モデル
    • ボランティア団体:一般/患者集団
    • 組織構造:公共/民間
  • バイオバンキングの指針と基準
  • バイオバンクベースの研究に対する法規
    • HIPAA改訂版
  • バイオバンキングと製薬産業
    • 研究・創薬・開発
    • 治療
    • 治験

第3章 世界の医療用バイオバンキング市場の予測

  • 世界の医療用バイオバンキング市場の実績
  • 医療用バイオバンキングの実績・予測:研究/治療用
  • 世界市場の収益予測
  • 部門別市場:グループ別収益予測
  • 研究用バイオバンキング:ほとんどが非営利
  • 将来の治療用途向けバイオバンキング:商業的過ぎるか?

第4章 研究用バイオバンキング

  • 組織タイプ別の内訳
  • 市場実績・予測:組織タイプ別の比較
  • 組織タイプ別収益予測
  • 研究用バイオバンキングの試料の数
  • ヒト組織:市場実績
  • ヒト組織:収益予測
  • ヒト組織:商用・公共部門別内訳
  • 幹細胞:市場実績
  • 幹細胞:収益予測
  • その他:市場実績
  • その他:収益予測

第5章 将来の治療用途向け幹細胞バンキング

  • 市場実績:幹細胞タイプ別
  • 収益比較・市場シェア:幹細胞タイプ別
  • グループ別収益予測
  • 貯蔵される幹細胞の規模
  • 臍帯血:市場実績
  • 臍帯血:収益予測
  • 成人幹細胞:市場実績
  • 成人幹細胞:収益予測

第6章 主要国市場の予測

  • バイオバンキングの地理的フットプリント
  • 医療用バイオバンキング:米国が先導
  • 主要国市場の収益予測:グループ別
  • 地域別シェアの変動予測
  • 米国
  • 欧州主要国
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • スペイン
    • オランダ
  • 日本
  • BRIC諸国
    • 中国
    • インフォ
    • ブラジル
    • ロシア

第7章 バイオバンキング技術:システム・ソフトウェア・消耗品・サービス

  • バイオバンキング関連市場の概要
  • システム技術:完全自動処理
  • 貯蔵技術:持続可能性・容易なサンプルトラッキング・セキュリティ
  • バイオバンク用ソフトウェア
  • 消耗品:効果的なサンプル管理に求められる高品質性
  • バイオバンキングサービス:生物試料の貯蔵・管理・輸送

第8章 バイオバンキング市場の主要企業

  • さまざまなビジネスモデル:調達 vs 保存
  • 研究目的の商業バイオバンク
    • Tissue Solutions
    • Asterand Bioscience
    • Biopta
    • BioServe
    • Coriell Institute for Medical Research
  • 治療用途の有望なバイオバンク
    • Cord Blood America
    • Cryo-Cell International
    • Cryo-Save
    • China Cord Blood Corp
    • LifebankUSA
    • ViaCord
    • Cord Blood Registry
    • Biogenea Pharmaceuticals
    • StemLife
    • Future Health Biobank
    • Caladrius Biosciences
    • Precious Cells

第9章 定性分析

  • 産業動向
  • 市場の強みと弱み
  • 市場機会と脅威
  • STEP分析

第10章 調査インタビュー

第11章 総論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0112

Biobanks - How to Discover Trends, R&D and Sales Forecasts from 2016, Helping Your Influence

Are you interested in the future of medical biobanking? If so, you can now gain technological and commercial predictions from 2016. That way you stay ahead for data, benefiting your authority. There explore trends in research and development, results, opportunities and revenue forecasts.

That new study by visiongain shows you what is possible for biobanking and associated technology for human healthcare. Avoid missing out. Instead find sales potentials for that biomedical industry and market, discovering expected trends, progress and financial gains.

Biobank services and technology exert great influence on drug discovery and development. That importance increases from 2016. See what the future holds.

Potential of those biorepository technologies and storage facilities

In medical research those biostorage systems form an important resource. They support fields including genomics and personalised medicine, letting companies store and use samples.

Our report's purpose is showing you the commercial potential in storing human biological samples for use in research and therapies, including conserving stem cells.

Please read on to explore those technologies and services for human medicine, finding what influences that market and seeing predicted revenue.

Forecasts and other information showing lucrative possibilities for biorepositories

Our study gives sales predictions to 2026 at overall world, submarket and national level. You also get sample unit predictions. For biosample and biospecimen storage, especially for pharmaceutical R&D, you investigate where applications, needs, demand and money lie.

Why struggle to find information or miss data you need on medical biopreservation? Besides revenue forecasting, our new analysis shows you results, growth rates and market shares.

There you explore those technologies for medical R&D - especially applications suiting drug companies. Our new report gives you 72 tables, 74 charts and three interviews with authorities in that field. Discover, from 2016, the potential of biobanks.

Forecasting of that world market and its segments - you find commercial prospects See in our report overall world revenue to 2026, with discussions, for storing human cell, tissue and fluid samples.

That way you can help your research, analyses and decisions on storage of human biological samples (HBS). As someone with authority, benefit your reputation for technological and commercial insight.

In particular find individual revenue predictions to 2026 for nine submarkets at world level:

  • Biobanking for research
  • Biobanking for therapeutic uses.

There you find biobanking revenue forecasting to 2026 by research application:

  • Human tissues - also with sub-forecasts for public sector and commercial uses
  • Stem cells
  • Other biological sample banking applications - inc. DNA and body fluids.

And our analysis predicts stem cell banking revenues to 2026 for therapeutic uses:

  • Umbilical cord stem cell banking
  • Adult stem cell banking.

You also get forecasts to 2026 for the number of samples banked for research and therapeutic applications.

In our study you assess outlooks for sales expansion, hearing where you could gain. That work explores competition and demand, showing technological and commercial possibilities.

So hear what is happening. You also investigate geographical revenue potentials.

Biostorage needs in leading national markets - what outlooks for demand, sales and capacity?

In developed and developing countries, opportunities for companies providing biorepository facilities, products, services, consumables and technology will expand from 2016.

Our analyses show you individual revenue forecasts to 2026 for 12 leading national biobanking markets:

  • The US
  • Japan
  • Germany, France, the UK, Italy, Spain and the Netherlands
  • Brazil, Russia, India and China.

There discover countries with highest sales, demand and potential expansion of usage and revenues. That way you investigate progress, needs, opportunities and competitors. And you see the gains possible, finding how you could expand your business.

Also what events, challenges and advances in technology affect biorepositories?

Forces influencing suppliers and users of those biomedical resources and libraries

Our new study explores issues, events and contributions affecting that industry and market from 2016, including these influences:

  • Guidelines, research and medical ethics, standards (e.g. GLP), legislation, regulations and governmental funding for that biopreservation, inc. HIPAA amendments
  • Systems for cryopreservation, biobank networks and biobanking infrastructure
  • Facilities, freezers, operations software, consumables and services
  • Biobanking in research, drug discovery and development, inc. biomarkers and personalised medicine
  • Uses in therapeutics, clinical trials and genome-wide association studies (GWAS).

And you explore these forces, among others:

  • Numbers and geographical distribution of biobanks
  • Umbilical cord blood banking and induced pluripotent stem cells (iPSCs)
  • RFID, tagging technology and laboratory information management systems (LIMS)
  • Technologies and services aiding genetic epidemiology studies and understanding of disease pathways
  • Automated liquid handling systems, and automation in DNA isolation
  • Biobanking services - sample storage, tracking, management and transport of human biological samples.

That way you find what stimulates and restrains organisations performing and helping that biosample preservation, affecting their results and those of biobank clients.

Technologies and applications - top organisations and 2020 market value

What future sales results are possible? Our study predicts that the world biobanking market will generate $27.5bn in 2020. Rising demand for biobanked samples for use by pharmaceutical companies in preclinical research most stimulates biobanking revenues.

Our analysis shows activities of biobanks, including these organisations:

  • Stemgent
  • Biopta
  • BioServe
  • Coriell Institute for Medical Research
  • Cord Blood America
  • Cryo-Cell International.

And other companies, including these:

  • China Cord Blood Corp
  • LifebankUSA
  • ViaCord
  • Cord Blood Registry
  • Biogenea Pharmaceuticals
  • StemLife
  • Caladrius Biosciences.

That way you assess competitors and developments. Our analysis includes interviews with Fidelis Research, Bulgaria, 3C-R, France, and the UK ME/CFS Biobank Project. So avoid missing out in knowledge. See what other authorities say and do, helping your work.

Five ways Biobanking Market Forecasts 2016-2026 helps your work

In these five main ways, our new investigation helps you get recognition for insight, saving time and benefiting your authority:

  • Revenues for biobanking, to 2026, at world level and for 9 submarkets - explore prospects for design, production, sales, marketing, demand and spending
  • Forecasts, to 2026, for 12 countries in the Americas, Europe and Asia - assess developed and developing national markets for demand and predicted revenues
  • Prospects for established organisations, rising companies and new entrants - examine service and product portfolios, results, strategies and outlooks for success
  • Analysis of what stimulates and restrains that industry's participants - investigate challenges, strengths and competition affecting organisations' results
  • Interviews with organisations - discover what authorities in that field say and do, helping you stay ahead in knowledge to help your work.

That report, by visiongain's UK-based analysts, gives knowledge to benefit your research, analyses, plans, decisions and proposals. You get data leading companies depend on.

Information there found nowhere else, helping your searches, analyses and planning

An off-the-shelf report cannot answer every question, though our work explains that industry's structures, outlooks and potentials.

Our analyses give independent data. There you get competitive intelligence found only in that study, finding where progress, money and opportunities lie. See what the future holds.

With that research and analysis you are less likely to fall behind in knowledge or miss opportunity. There see how you could save time and effort. And benefit your plans, decisions and presentations, helping you gain advantages and recognition.

Trying our study now lets you discover biobanking opportunities and predictions

Stay ahead in data. Our new investigation is for everyone analysing medical biotechnology and pharmaceutical R&D. For storing biological samples you see trends, opportunities and revenue predictions. So avoid missing out - please get our new report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Biobanking for Medicine: World Market Review 2015 and Global Segmentation
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to Biobanking and its Applications

  • 2.1. Defining the Human Tissue Banking Market for the Scope of this Report
  • 2.2. The Stem Cell Banking Market - Our Breakdown
  • 2.3. What is Biobanking?
  • 2.4. Main Features of Biobanks
  • 2.5. What Processes are Involved in Biobanking?
  • 2.6. Classification of Biobanks: Tissue Type, Volunteer Group and Ownership Classification Models
    • 2.6.1. Volunteer Group: General vs. Disease Population
    • 2.6.2. Ownership Structure: Public vs. Private
  • 2.7. The Guidelines and Standards for Biobanking
  • 2.8. Laws and Regulations for Biobank-Based Research
    • 2.8.1. HIPAA Amendments
  • 2.9. Biobanking and the Pharmaceutical Industry
    • 2.9.1. Biobanking in Research, Drug Discovery and Development
      • 2.9.1.1. Biobanking - Facilitates Genetic Epidemiology Studies
      • 2.9.1.2. Novel Drug Discovery through Better Understanding of Disease Pathways
      • 2.9.1.3. Biomarker Discovery in Drug Development
    • 2.9.2. Biobanking for Therapeutic Purposes
    • 2.9.3. Biobanking in Clinical Trials

3. Biobanking for Medicine: World Market 2015 to 2026

  • 3.1. The World Biobanking for Medicine Market in 2015
  • 3.2. Biobanking for Medicine: Research vs. Therapeutics in 2020 and 2026
  • 3.3. World Biobanking for Medicine Market: Overarching Revenue Forecast 2015 to 2026
  • 3.4. Biobanks Stored More Than 1.4 Billion Specimens in 2015
  • 3.5. The Biobanking for Medicine Market by Sector: Grouped Revenue Forecasts 2015 to 2026
  • 3.6. Biobanking for Research: Mostly Non-Profit
    • 3.6.1. Biobanking for Research: Revenue Forecast 2015 to 2026
    • 3.6.2. Driving Forces: Outweighs Restraints on the Biobanking Industry for Research
  • 3.7. Biobanking for Future Therapeutic Use: Is It Too Commercial?
    • 3.7.1. Arguments against Commercial Stem Cell Banking for Therapeutic Uses
    • 3.7.2. Biobanking for Future Therapeutic Use: Revenue Forecast 2015 to 2026
    • 3.7.3. Driving and Restraining Forces Influencing the Biobanking Market for Therapeutic Applications, 2015 to 2026

4. Biobanking for Research Purposes

  • 4.1. Breakdown of Biobanking for Research Market by Tissue Type, 2015
  • 4.2. Biobanking for Research in 2020 and 2026: Comparison by Tissue Type
  • 4.3. Biobanking for Research by Tissue Type: Grouped Revenue Forecasts 2015 to 2026
  • 4.4. How Many Specimens are Biobanked for Research?
  • 4.5. The Human Tissue Banking Market for Research in 2015
  • 4.6. The Human Tissue Banking Market for Research: Revenue Forecast 2015 to 2026
  • 4.7. The Human Tissue Banking Market: Commercial vs. Public Sectors
    • 4.7.1. Commercial Human Tissue Banks: Revenue Forecast 2015 to 2026
    • 4.7.2. Public Sector Human Tissue Banks: Revenue Forecast 2015 to 2026
  • 4.8. The Stem Cell Banking Market for Research in 2015
  • 4.9. The Stem Cell Banking Market for Research: Revenue Forecast 2015 to 2026
    • 4.9.1. R&D- Growing Interest Towards iPSCs
  • 4.10. Banking of Other Biologics Specimens for Research in 2015
  • 4.11. Banking of Other Biologic Specimens for Research: Revenue Forecast 2015 to 2026

5. Stem Cell Banking for Future Therapeutic Use

  • 5.1. Stem Cell Banking for Therapeutic Use in 2015: A Breakdown by Stem Cell Type
  • 5.2. Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenue and Market Share, 2020 and 2026
  • 5.3. Stem Cell Banking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts
  • 5.4. How Many Stem Cells Are Biobanked Each Year?
  • 5.5. The Umbilical Cord Blood Banking Market in 2015
    • 5.5.1. Private vs. Public Cord Blood Banking
    • 5.5.2. Umbilical Cord Blood Banking: The Controversies
  • 5.6. The Umbilical Cord Blood Banking Market: Revenue Forecast 2015 to 2026
  • 5.7. The Adult Stem Cell Banking Market in 2015
  • 5.8. The Adult Stem Cell Banking Market: Revenue Forecast 2015 to 2026

6. Leading National Markets 2015 to 2026

  • 6.1. The Geographical Footprint of Biobanking
    • 6.1.1. Biobanking in Europe: Leading the World with Biobanking Networks and Infrastructure
    • 6.1.2. Biobanks in the US: A Fragmented Picture
    • 6.1.3. Biobanking in Asia: A Region Fast Gaining Prominence
  • 6.2. Biobanking for Medicine: The US Led the Way in 2015
  • 6.3. The Leading National Markets: Grouped Revenue Forecasts 2015 to 2026
  • 6.4. How Will Regional Market Shares Change to 2026?
  • 6.5. The US Biobanking Market 2015 to 2026: Diversifying and Expanding
  • 6.6. The Top European Biobanking Markets 2015 to 2026: Leading the Way in Biobanking Infrastructure
    • 6.6.1. Germany: An Advanced Industry with 74 Biobanks Associated with the BBMRI
    • 6.6.2. France: Restrictions on Private Stem Cell Banking Limit the Market
    • 6.6.3. Italy: Is the Limited Private Stem Cell Banking Market Off-Set by Strong Biobanking Networks for Research?
    • 6.6.4. UK: Limited Presence of Biobanking Networks
    • 6.6.5. Spain: Controversy Between Private and Public Umbilical Cord Blood Banks
    • 6.6.6. The Netherlands is Characterised by Comprehensive Biobanking Networks
  • 6.7. The Japanese Biobanking Market 2015 to 2026: A High Level of Government Investment Drives Growth
  • 6.8. The Biobanking Industry in the BRIC Countries: High Growth and Increasing Market Share between 2015 and 2026
    • 6.8.1. The Chinese Biobanking Market 2015 to 2026: The High Rate of Growth Will Continue
    • 6.8.2. The Indian Biobanking Market 2015 to 2026: Set to Become the Leading Market for Private Stem Cell Banking?
    • 6.8.3. The Brazilian Biobanking Market 2015 to 2026: Will New Regulations Drive or Restrain the Market?
    • 6.8.4. Russia: Ban on the Import and Export of Human Tissue and Genetic Information Restricts the Market, But Can This Be Overcome from 2015 to 2026?

7. Technology for Biobanking: Systems, Software, Consumables and Services Associated with Biobanking

  • 7.1. The Biobanking-Associated Market: Overview
  • 7.2. Systems Technology: Fully Automated Handling
    • 7.2.1. Automated Liquid Handling Systems
    • 7.2.2. Frozen Aliquoting: Patented Technology from CryoXtract
    • 7.2.3. Automated DNA Isolation
  • 7.3. Storage Technology: Sustainability, Easy Sample Tracking, and Added Security
    • 7.3.1. Dry State, Room Temperature Storage Eliminates the Need for Expensive, Energy-Consuming Freezers
    • 7.3.2. Ultra-Low Temperature Freezers: Is Their Use Declining?
    • 7.3.3. Cryopreservation: Mechanical vs. Liquid/ Vapour Phase Nitrogen
    • 7.3.4. Automated Storage and Retrieval Systems: Essential Technology
    • 7.3.5. RFID and Tagging Technology: Advantages over Barcodes
  • 7.4. Software for Biobanks
    • 7.4.1. Laboratory Information Management System (LIMS): Unmet Needs in the Market Remain, Despite Recent Advances
    • 7.4.2. LIMS Functions
  • 7.5. Consumables: High Quality Required for Effective Sample Management
    • 7.5.1. Addressing Sample Storage and Tracking Issues
  • 7.6. Biobanking Services: Storage, Management and Transport of Biologic Samples for a Fee

8. Leading Companies in the Biobanking Market

  • 8.1. The Differing Business Models of Biobanking Companies: Sourcing vs. Storing
  • 8.2. Commercial Biobanks for Research Purposes in 2015
    • 8.2.1. Tissue Solutions: A Virtual Biobank with a Global Presence
      • 8.2.1.1. An Overview of the Products and Services Offered by Tissue Solutions
      • 8.2.1.2. Banked Samples Occur in Many Formats
      • 8.2.1.3. Prospective Tissue Collection for Hard-to-Find Samples
      • 8.2.1.4. Fresh Samples from Surgical Resections are in High Demand
      • 8.2.1.5. Freshly Isolated Human Cells are a Valuable Research Tool
      • 8.2.1.6. FDA/ EMA Panel of Normal Tissues
      • 8.2.1.7. Strengths, Capabilities and the Future Outlook for Tissue Solutions
    • 8.2.2. Asterand Bioscience is now Part of Stemgent
      • 8.2.2.1. Asterand's Products and Services: XpressBANK, BioSpoke and PhaseZERO
      • 8.2.2.2. The Future Outlook for Asterand
    • 8.2.3. Biopta: Human Tissue Provider Now Acquired by Japanese Company ReproCELL
      • 8.2.3.1. Services from Biopta: A Variety of Lab Services and Fresh Tissue Sample Procurement
      • 8.2.3.2. The First Catalogue of Assays Based on Human Functional Tissues
      • 8.2.3.3. The Future Outlook for Biopta: Fresh Tissue Will Be in Demand
    • 8.2.4. BioServe: One of the World's Largest Commercial Biorepositories
      • 8.2.4.1. BioServe Offers a Comprehensive List of Services: Biobanking, Sourcing and Preclinical Molecular Services
      • 8.2.4.2. The Future Outlook for BioServe
    • 8.2.5. Coriell Institute for Medical Research: Reportedly the Largest Biobank in the World
      • 8.2.5.1. Features of and Recent Developments at Coriell Biobank
      • 8.2.5.2. Future Outlook for the Coriell Biobank
  • 8.3. Prominent Biobanks for Therapeutic Use in 2015
    • 8.3.1. Cord Blood America: Expansion into the Emerging Markets Apparently Stalled, Strategic Alternatives Being Considered
    • 8.3.2. Cryo-Cell International: The First Private Cord Blood Bank in the Market
    • 8.3.3. Cryo-Save's Educational Programme Benefits Company's Growth
    • 8.3.4. China Cord Blood Corp: The Only Cord Blood Bank in China with Multiple Licences Is Under a New Owner
    • 8.3.5. LifebankUSA: Acquisition from Human Longevity Inc Will Potentially Drive Growth
    • 8.3.6. ViaCord: More Blood Units Released for Therapy than Any Other Family Bank
    • 8.3.7. Cord Blood Registry: The World's Largest Newborn Stem Cell Company Will Be Promoted By New Parent Company
    • 8.3.8. Biogenea Pharmaceuticals: A Comprehensive Offering of Stem Cell Banking Services across the Balkan Peninsula
    • 8.3.9. StemLife is Reportedly Facing Challenges Due to Government Regulations in Malaysia
    • 8.3.10. Future Health Biobank: A Strong Market Presence Owing to International Operations
    • 8.3.11. Caladrius Biosciences (formerly NeoStem): More Focus on Cell Therapy Than Stem Cell Banking
    • 8.3.12. Precious Cells is Well Positioned to Take Advantage of the Growing Demand in India

9. Qualitative Analysis of the Biobanking Market 2015 to 2026

  • 9.1. Industry Trends
    • 9.1.1. The Growing Demand for Biobank Resources for Research
    • 9.1.2. The Establishment of Biobanking Networks
      • 9.1.2.1. BBMRI: The Most Extensive Biobank Network
    • 9.1.3. Virtual Biobanks: Connecting a Fragmented Industry
    • 9.1.4. Commercial Biobanks as Intermediaries: New Resources for Research
    • 9.1.5. Automated Biobanking Has Become Imperative
    • 9.1.6. Increasing Uptake of LIMS
    • 9.1.7. Green Banking - Becoming More Energy Efficient
  • 9.2. The Strengths and Weaknesses of the Biobanking Market in 2015
    • 9.2.1. HBS are Valuable Resources for R&D
    • 9.2.2. Governmental Support for Biobanking Forms a Strength of that Industry
    • 9.2.3. Development of Potential Novel Stem Cell Therapies has Increased Public Awareness of Stem Cell Banking
    • 9.2.4. The Effect of Big Data on Biobanking
    • 9.2.5. Insufficient Accessible Numbers of High Quality Biospecimens
    • 9.2.6. Biobanks are Fragmented and Uncoordinated
    • 9.2.7. Lack of Standardisation is a Weakness of the Industry
    • 9.2.8. Lack of Public Awareness Limits Number of Donors
    • 9.2.9. Lack of Engagement with Public Health Services Limits the Stem Cell Banking Market
  • 9.3. Opportunities and Threats Facing the Biobanking Market, 2015 to 2026
    • 9.3.1. Increasing Use of Biobanked Specimens in Genome-Wide Association Studies (GWAS)
    • 9.3.2. Increasing Demand for Biobanked Samples for Preclinical Research
    • 9.3.3. Biobanking Networks as a Basis for Personalised Medicine
    • 9.3.4. Options for Adult Stem Cell Banking Mean an Increasing Target Population for Private Stem Cell Banks
    • 9.3.5. Even With Governmental Funding, Biobanks Must Become Self-Sufficient to Thrive Long-Term
    • 9.3.6. Public Concerns over Confidentiality and Security Threaten Availability of Donors
    • 9.3.7. Limitations Surrounding Informed Consent
  • 9.4. Social, Technological, Economic and Political Factors (STEP) Influencing the Biobanking Industry, 2015 to 2026

10. Research Interviews

  • 10.1. Mr Veselin D. Stefanov, MBA, General Manager, Fidelis Research, Bulgaria
    • 10.1.1. Fidelis Research - Specialists in Human Tissue Procurement With a Strong Network of Partners
    • 10.1.2. Challenges in Tissue Procurement Stem from a Lack of Legislation
    • 10.1.3. Lack of Standardisation Causing Decreased Demand for Biobanked Tissues
    • 10.1.4. Significant Therapeutic Areas of Demand
    • 10.1.5. Essential Qualities for a Successful Tissue Procurement Service
    • 10.1.6. The Impact of Trends in Biobanking
  • 10.2. Dr Jeanne-Hélène di Donato, 3C-R, France
    • 10.2.1. French Biobanks - a Network of Specialized Biobanks
    • 10.2.2. Biobanking Management -Promoting Scientific Value of Collections
    • 10.2.3. Harmonization - Scientific Valorisation
    • 10.2.4. Bioethical - Diverse Views and Policies on Consent
    • 10.2.5. Broad Consent -Is This the Best Option?
    • 10.2.6. 3C-R - Services and Solutions for Biobanks
  • 10.3. Dr Luis Nacul and Dr Eliana Lacerda, UK ME/CFS Biobank Project
    • 10.3.1. UK ME/CFS Biobank - Objectives and Activities
    • 10.3.2. Biobank Resource - Available for External Researchers in August 2015
    • 10.3.3. Main Issue - Sustainability
    • 10.3.4. Unmet Needs - Awareness from Government and General Public

11. Conclusions from Our Research and Analysis

  • 11.1. World Biobanking Market 2015 to 2026: High Revenue Growth Predicted
  • 11.2. Biobanking for Research 2015 to 2026: The Value of Biobanked Specimens is Increasingly Recognised
  • 11.3. Biobanking for Therapeutic Use 2015 to 2026: Rapid Expansion in Adult Stem Cell Banking
  • 11.4. The Leading National Markets: High Sales Growth Worldwide
  • 11.5. Current and Future Trends in Biobanking
    • 11.5.1. Increasing Demand for Biobanked Samples - Increasing Revenue
    • 11.5.2. Improving Biobanking Infrastructure - Growth Driver and a Need for Strategic Planning for Sustainability
    • 11.5.3. Marked Challenges, but Opportunities for Expansion

List of Tables

  • Table 2.1: Prominent Population-Based Biobanks, 2016
  • Table 2.2: Prominent Disease-Based Biobanks, 2014
  • Table 2.3: Guidelines and Recommendations for Biobanks, 2014
  • Table 2.4: Laws and Other Regulations for Biobank-Based Research by Country/ Organisation 2016
  • Table 2.5: Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2014
  • Table 3.1: Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($bn) and Market Share (%), 2015
  • Table 3.2: Breakdown of the Biobanking Industry by Research vs. Therapeutics: Comparison of Revenues ($bn) and Market Shares (%), 2020 and 2026
  • Table 3.3: Biobanking for Medicine: Overall World Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 3.4: Number of Samples Stored in Biobanks by Purpose: Overall World Forecast, Number of Samples (m), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 3.5: Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 3.6: Biobanking Market for Research Forecast: Revenue ($bn) Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 3.7: Biobanking for Therapeutic Use Forecast: Revenue ($bn) Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 4.1: The Biobanking for Research Market by Tissue Type: Revenues ($bn) and Market Shares (%), 2015
  • Table 4.2: Biobanking for Research by Tissue Type: A Comparison of Revenues ($bn) and Market Shares (%), 2020 and 2026
  • Table 4.3: Biobanking for Research by Tissue Type: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 4.4: Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 4.5: Human Tissue Banking Market Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 4.6: The Commercial vs. Public Sector Human Tissue Banking Market: Comparison of Revenues ($bn) and Market Shares (%), 2015, 2020 and 2026
  • Table 4.7: The Human Tissue Banking Market Forecasts by Subsector: Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 4.8: Commercial Human Tissue Banking Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 4.9: Prominent Commercial Human Tissue Banks, 2014
  • Table 4.10: Public Sector Human Tissue Banking Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 4.11: Prominent Public-Funded Human Tissue Banks, 2014
  • Table 4.12: The Stem Cell Banking Market for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 4.13: Prominent Stem Cell Banks Serving the Research Community, 2014
  • Table 4.14: Banking of Other Biologic Specimens for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 4.15: Prominent Biobanks Storing Other Biologic Samples, 2014
  • Table 5.1: Biobanking for Therapeutic Use by Stem Cell Type: Revenues ($bn) and Market Shares (%), 2015
  • Table 5.2: Biobanking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn) and Market Shares (%), 2020 and 2026
  • Table 5.3: Biobanking for Therapeutic Use by Stem Cell Type: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 5.4: The Number of Stem Cell Samples Banked for Therapeutic Use: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 5.5: Prominent Public and Private Cord Blood Banks, 2014
  • Table 5.6: The Umbilical Cord Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 5.7: Prominent Companies in the Adult Stem Cell Banking Industry, 2014
  • Table 5.8: The Adult Stem Cell Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.1: Breakdown of BBMRI Network Directory Members by Country, 2016
  • Table 6.2: The Leading National Biobanking Markets: Comparison of Revenues ($bn) and Market Shares (%), 2015
  • Table 6.3: Leading National Markets Grouped Forecasts Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.4: Leading National Markets: Comparison of Market Shares (%), 2015, 2020 and 2026
  • Table 6.5: Biobanking for Medicine in the US Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.6: The Leading European Markets for Biobanking Grouped Forecasts: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.7: Examples of Biobanking Initiatives Funded by the European Commission, 2016
  • Table 6.8: The German Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.9: The French Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.10: The Italian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.11: The UK Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.12: The Spanish Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.13: Prominent Clinical and Population Biobanks in the Netherlands, 2016
  • Table 6.14: The Netherlands Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.15: The Japanese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.16: The Biobanking Industry in the BRIC Countries Grouped Forecasts: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.17: The Chinese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.18: The Indian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.19: Prominent Research Biobanks in India, 2016
  • Table 6.20: The Brazilian Biobanking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 6.21: The Russian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
  • Table 7.1: Prominent Companies Providing Automated Liquid Handling Technology, 2016
  • Table 7.2: Prominent Companies Providing Room Temperature Storage Solutions, 2016
  • Table 7.3: Prominent Companies Providing Ultra-Low Temperature Freezers (-80°C), 2016
  • Table 7.4: Mechanical Freezing vs. Liquid Nitrogen: Comparison of Advantages and Disadvantages, 2014
  • Table 7.5: Prominent Companies Providing Cryogenic Storage Solutions, 2016
  • Table 7.6: Prominent Providers of Automated Biobanking Systems, 2016
  • Table 7.7: Major Vendors in the LIMS Market, 2016
  • Table 7.8: Prominent Vendors of Consumables for Biobanking, 2016
  • Table 7.9: Prominent Biorepository Service Providers, 2016
  • Table 8.1: Prominent Players in the Biobanking Industry for Research, 2016
  • Table 8.2: Prominent Companies in the Stem Cell Banking Industry for Therapeutic Use, 2016
  • Table 8.3: China Cord Blood Corp: Revenue ($m), Total Units Stored for Subscribers, and No. Of New Subscribers, 2013 to 2015
  • Table 8.4: StemLife: Comparison of Revenue ($m) between 2014 and 2015
  • Table 9.1: Strengths and Weaknesses of the Biobanking Industry, 2016
  • Table 9.2: Opportunities and Threats Facing the Biobanking Industry, 2015 to 2026
  • Table 9.3: Social, Technological, Economic and Political (STEP) Forces Influencing the Biobanking Industry, 2015 to 2026

List of Figures

  • Figure 1.1: Global Biobanking Industry Segmentation Overview, 2016
  • Figure 2.1: Processes Involved in Biobanking, 2016
  • Figure 2.2: The Classification of Biobanks, 2016
  • Figure 3.1: Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2015
  • Figure 3.2: Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2020
  • Figure 3.3: Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2026
  • Figure 3.4: Biobanking for Medicine: Overarching Revenue Forecast ($bn), 2015 to 2026
  • Figure 3.5: The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast, No. of Samples (m), 2015 to 2026
  • Figure 3.6: Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), 2015 to 2026
  • Figure 3.7: Biobanking Market for Research: Revenue Forecast ($bn), 2015 to 2026
  • Figure 3.8: Biobanking for Research: Drivers and Restraints, 2015 to 2026
  • Figure 3.9: Biobanking for Therapeutic Use: Revenue Forecast ($bn), 2015 to 2026
  • Figure 3.10: Biobanking for Therapeutic Use: Drivers and Restraints, 2015 to 2026
  • Figure 4.1: The Biobanking for Research Market by Tissue Type: Market Shares (%), 2015
  • Figure 4.2: Biobanking for Research by Tissue Type: Market Shares (%), 2020
  • Figure 4.3: Biobanking for Research by Tissue Type: Market Shares (%), 2026
  • Figure 4.4: Biobanking for Research by Tissue Type: Grouped Revenue Forecasts ($bn), 2015 to 2026
  • Figure 4.5: Biobanking for Research: Market Drivers and Restraints, 2015 to 2026
  • Figure 4.6: Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), 2015 to 2026
  • Figure 4.7: The Human Tissue Banking Market: Revenue Forecast ($bn), 2015 to 2026
  • Figure 4.8: Human Tissue Banking for Research: Market Drivers and Restraints, 2015 to 2026
  • Figure 4.9: The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2015
  • Figure 4.10: The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2020
  • Figure 4.11: The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2026
  • Figure 4.12: The Human Tissue Banking Market by Subsector: Revenue Forecasts ($bn), 2015 to 2026
  • Figure 4.13: Commercial Human Tissue Banking: Revenue Forecast ($bn), 2015 to 2026
  • Figure 4.14: Public Sector Human Tissue Banking: Revenue Forecast ($bn), 2015 to 2026
  • Figure 4.15: The Stem Cell Banking Market for Research: Revenue Forecast ($bn), 2015 to 2026
  • Figure 4.16: Stem Cell Banking for Research: Market Drivers and Restraints, 2015 to 2026
  • Figure 4.17: Banking of Other Biologic Specimens for Research: Revenue Forecast ($bn), 2015 to 2026
  • Figure 4.18: Biobanking of Other Biologic Specimens for Research: Market Drivers and Restraints, 2015 to 2026
  • Figure 5.1: Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2015
  • Figure 5.2: Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2020
  • Figure 5.3: Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2026
  • Figure 5.4: Biobanking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts ($bn), 2015 to 2026
  • Figure 5.5: The Number of Stem Cell Samples Banked for Therapeutic Use (m): Forecast 2015 to 2026
  • Figure 5.6: The Stem Cell Banking Market for Future Therapeutic Use: Drivers and Restraints, 2015 to 2026
  • Figure 5.7: The Umbilical Cord Banking Market: Revenue Forecast ($bn), 2015 to 2026
  • Figure 5.8: The Umbilical Cord Blood Banking Market: Drivers and Restraints, 2015 to 2026
  • Figure 5.9: The Adult Stem Cell Banking Market: Revenue Forecast ($bn), 2015 to 2026
  • Figure 5.10: The Adult Stem Cell Banking Market: Drivers and Restraints, 2015 to 2026
  • Figure 6.1: The Leading National Biobanking Markets: Market Shares (%), 2015
  • Figure 6.2: The Leading National Markets: Grouped Revenue Forecasts ($bn), 2015 to 2026
  • Figure 6.3: The Leading National Markets: Market Shares (%), 2015
  • Figure 6.4: The Leading National Markets: Market Shares (%), 2020
  • Figure 6.5: The Leading National Markets: Market Shares (%), 2026
  • Figure 6.6: Biobanking for Medicine in the US: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.7: Driving and Restraining Factors of the US Biobanking Market, 2015 to 2026
  • Figure 6.8: The Leading European Markets for Biobanking: Grouped Revenue Forecasts ($bn), 2015 to 2026
  • Figure 6.9: Biobanking in the Leading European Countries: Driving and Restraining Factors, 2015 to 2026
  • Figure 6.10: The German Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.11: The French Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.12: The Italian Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.13: The UK Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.14: The Spanish Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.15: The Netherlands Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.16: The Japanese Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.17: Driving and Restraining Factors Influencing the Japanese Biobanking Industry, 2015 to 2026
  • Figure 6.18: The Biobanking Industry in the BRIC Countries: Grouped Revenue Forecasts ($bn), 2015 to 2026
  • Figure 6.19: Driving and Restraining Factors of the Biobanking Industry in the BRIC Countries, 2015 to 2026
  • Figure 6.20: The Chinese Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.21: The Indian Biobanking Industry: Revenue ($bn) Forecast, 2015 to 2026
  • Figure 6.22: The Brazilian Biobanking Market: Revenue Forecast ($bn), 2015 to 2026
  • Figure 6.23: The Russian Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
  • Figure 7.1: Structure of the Biobanking Industry: Biobanking-Associated Market, Biobanks and End Users, 2016
  • Figure 7.2: The Basic Function of LIMS
  • Figure 8.1: Biobanking Business Model: Commercial Sourcing of Biological Samples, 2016
  • Figure 8.2: Business Model: Commercial Banking of Biological Samples, 2016
  • Figure 8.3: China Cord Blood Corp: Revenue ($m), 2013 to 2015
  • Figure 8.4: StemLife: Comparison of Revenue ($m), 2013 and 2014
  • Figure 11.1: The Global Biobanking Market by Industry Sector: Comparison of Revenues ($bn), 2015, 2020 and 2026
  • Figure 11.2: Biobanking for Research by Sample Type: Comparison of Revenues ($bn), 2015, 2020 and 2026
  • Figure 11.3: Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn), 2015, 2020 and 2026
  • Figure 11.4: Leading Regional Markets for Biobanking: Comparison of Revenues ($bn), 2015, 2020 and 2026

Companies Listed

  • 3C-R
  • 100,000 Genomes Project
  • Abbott Laboratories
  • Accelrys
  • AdeptBio
  • Adnexus Therapeutics
  • Advanced Innovative Medicine
  • AIS
  • AKH Biobank
  • AllCells
  • Allied Minds
  • AlloSource
  • AMAG Pharmaceuticals
  • American Association of Tissue Banks
  • American CryoStem
  • American Type Culture Collection (ATCC)
  • Amgen
  • Analytical Biological Services
  • ARUP Laboratories
  • ASPREE Healthy Ageing Biobank
  • AssureImmune
  • Asterand Biosciences
  • AstraZeneca
  • Aurora Biomed
  • Australian Biospecimen Network (ABN)
  • Autoscribe Informatics
  • AuxoCell Laboratories
  • AXM Shenyang
  • Bangalore Brain Bank
  • Barts Gynae Tissue Bank
  • Bavarian Red Cross (BRK)
  • Bayer
  • BBMRI
  • Beckman Coulter
  • Benelux
  • BINDER
  • Biobank Ireland Trust
  • BioCision
  • Biocordcell Argentina
  • BioEden
  • BioFortis
  • Biogen Idec
  • Biogenea
  • Biogenea Pharmaceuticals
  • BioLife Solutions
  • Biomatrica
  • Biomedical Research Council (BMRC)
  • Biopta
  • BioreclamationIVT
  • BioRep
  • BioRepository Resources
  • Bioserve Biotechnologies
  • BioServe Biotechnologies India
  • BioStorage Technologies
  • Biovault Technical
  • BIOVIA
  • Bluechiip Ltd.
  • BrainNet Europe
  • Bristol-Myers Squibb
  • British Birth Cohort
  • Brooks
  • Brooks Life Science Systems
  • Caladrius Biosciences
  • Cambridge Biomedical Research Centre
  • Cambridge Biosciences
  • Canadian Partnership for Tomorrow
  • Cancer Genetics Inc
  • Cancer Genetics India
  • Cancer Human Biobank (caHUB)
  • CCLG Tissue Bank
  • Celgene Cellular Therapeutics
  • Cells4Life
  • Celltex Therapeutics
  • Cellular Dynamics
  • Center for iPS Cell Research and Applications (CiRA)
  • Centro Nazionale per le Risorse Biologiche (CNRB)
  • Cesca Therapeutics
  • Chernobyl Tissue Bank
  • China Cord Blood Corp.
  • China Kadoorie Biobank
  • China Stem Cells
  • CIRM (California Institute of Regenerative Medicine)
  • CLB/Amsterdam Medical Center
  • Clinical Proteomic Tumor Analysis Consortium (CPTAC)
  • CMD Biobank
  • CONCOR
  • CorCell
  • Cord Blood Registry (CBR)
  • CordBlood America
  • CordLife
  • CordVida
  • CORE Informatics
  • Coriell Institute for Medical Research
  • Council of Europe (CoE)
  • Covance
  • Croydon NHS Trust
  • Cryo Bio System
  • Cryo Save
  • Cryo-Cell International
  • Cryogene Lab
  • CryoLogic
  • Cryopraxis
  • CryoXtract Instruments
  • Cureline
  • Custom Biogenic Systems
  • Cybrdi
  • Daifuku
  • Danubian Biobank Consortium
  • deCODE Genetics
  • Deloitte
  • Scottish Government
  • Eli Lilly
  • EMA
  • Eppendorf
  • Esco
  • Estonian Genome Center
  • European Association for Predictive, Preventative & Personalised Medicine (EPMA)
  • European Bank for induced pluripotent stem cells (EBiSC)
  • European Commission (EC)
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Health Risk Monitoring (EHRM)
  • European Research Infrastructure Consortium (ERIC)
  • European Union Group on Ethics (EGE)
  • FDA
  • Fidelis Research
  • Fisher BioServices
  • FluidX
  • Fox Chase Cancer Centre
  • Future Health Biobank
  • GC Biotech
  • GE Healthcare
  • GE Healthcare SeqWright Genomic Services
  • Genentech
  • GenVault
  • Germany Cryo
  • Gilson
  • GlaxoSmithKline
  • Golden Meditech Holdings
  • H. Lee Moffitt Cancer Center and Research Institute
  • Haier Biomedical
  • Hamilton
  • Hamilton Robotics
  • Hamilton Storage Technologies
  • Harvard Stem Cell Institute
  • Hitachi Chemical
  • Hospital Necker Paris
  • Hubris (HUNT Biobank Resource Information System)
  • Hudson Robotics
  • Human Genome Project
  • Human Longevity
  • Human Science Research Resource Bank (HSRRB)
  • Human Tissue Bank
  • Hungarian Biobank
  • HUNT Norway
  • Huntington Disease Biobank
  • ILSBio
  • Imperial Tissue Bank
  • Inbiomed
  • Indian Institute of Technology
  • Indivumed
  • Infectious Disease Biobank
  • INSERM
  • Instituto de Salud Carlos III (ISCIII)
  • IntegenX
  • International Agency for Research on Cancer (IARC)
  • International Organization for Standardization
  • International Society for Biological and Environmental Repositories (ISBER)
  • International Stem Cell Corporation
  • Japan Health Sciences Foundation
  • Kaiser Permanente
  • King's College London Tissue Bank
  • KORAgen
  • Kyoto University
  • Labtech
  • Labvantage Solutions
  • Labware
  • LBD Life Sciences
  • Leiden Longevity
  • Leiden University Medical Center
  • LifeBank USA
  • LifeCell
  • LifeGene
  • LifeLines Biobank
  • Malmo Microbiology Biobank
  • MatriCal Biosciences
  • Medical Research Council
  • Merck & Co.
  • Merck-Serono
  • Micronic
  • Minister of State for Public Health
  • Ministry of Health and Welfare
  • Mitochondrial Disease Biobank
  • MSD
  • Nanjing Xinjiekou Department Store Co.
  • Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center
  • National Cancer Institute (NCI)
  • National Health and Family Planning Commission (NHFPC)
  • National Institute of Standards and Technology (NIST)
  • National Institutes of Biomedical Innovation, Health and Nutrition (NIBHN)
  • National Institutes of General Medical Sciences (NIGMS)
  • National Institutes of Health (NIH)
  • NeoStem
  • NESDA
  • Netherlands Twin Registry
  • NHS Blood and Transplant Cord Blood Bank
  • NIGMS Human Genetic Cell Repository
  • Northwest Regional Development Agency
  • Novare Biologistics
  • Novartis
  • Ocimum Biosolutions
  • Office of Biorepositories and Biospecimen Research (OBBR)
  • OnCore UK
  • Organisation for Economic Co-operation and Development (OECD)
  • OriGene
  • P3G Consortium (Public Population Projects in Genomics)
  • Pacific BioStorage
  • PALGA
  • Panasonic Biomedical
  • Parelsnoer
  • PerkinElmer
  • Pfizer
  • Pharmacells
  • Pharmagene
  • Pop-Gen National Cohort
  • Precious Cells
  • Precision Bioservices
  • PrecisionMed
  • PREVEND
  • Progenicyte
  • Progenitor Cell Therapy (PCT)
  • ProMedDx
  • Promega
  • ProteoGenex
  • Provia Labs
  • Qiagen
  • RAND
  • ReproCELL Group
  • Riken BRC Cell Bank
  • Roche
  • Rotterdam Study
  • RTS Life Sciences
  • Russian Society of Personalised Medicine (RSPM)
  • Saneron CCEL Therapeutics
  • Sanofi
  • Sapien Biosciences
  • Sartorius Stedim Biotech
  • Sceil
  • Seattle Genetics
  • Sechenov First Moscow Medical University (SFMMU)
  • S-Evans Biosciences (SEB)
  • Singapore Biobank (SBB)
  • Singapore Cord Blood Bank
  • Singapore Tissue Network (STN)
  • Smart Cells
  • Spanish Ministry of Science and Innovation (MICINN)
  • Spanish National Biobank Network
  • Stanford Tissue Bank
  • Stanford University
  • StarLIMS
  • Steelgate
  • Stellacure
  • Stem Cells for Safer Medicine
  • Stemcyte
  • Stemgent
  • StemLife
  • StemSave
  • Swedish Institute for Infectious Disease Control Biobank
  • System Biosciences
  • Taiyo Nippon Sanso
  • TAP Biosystems
  • Tata Memorial Hospital Tissue Bank
  • TCG Life Sciences Tissue Bank
  • TCGA (The Cancer Genome Atlas Project)
  • Tecan
  • The Cambridge Brain Bank
  • The Centre for Integrated Genomic Medical Research
  • The Guangzhou Biobank
  • The National Cancer Tissue Bank
  • Thermo Genesis
  • Thermo Scientific
  • Tissue Solutions
  • Titan Pharmaceuticals
  • Totipotent
  • TRT (Tissue Regeneration Therapeutics)
  • TTP Labtech
  • UCL Biobank
  • UK Biobank
  • UK Blood Service Collection
  • UK ME-CFS Biobank
  • UK Multiple Sclerosis Tissue Bank
  • UK Parkinson's Disease Tissue Bank
  • UK Stem Cell Bank
  • UK Stem Cell Strategic Forum
  • University of South Florida
  • University of Tüebingen
  • US Biomax
  • US Department of Transportation's (DOT's)
  • V.A. Almazov Federal Center for Heart, Blood and Endocrinology
  • ViaCell
  • ViaCord
  • VidaPlus
  • Virgin Health Bank
  • Wellcome Trust
  • Wellcome Trust Case-Control Consortium (WTCCC)
  • Wheaton
  • Wisconsin International Stem Cell (WISC) Bank
  • World Health Organization (WHO)
Back to Top